ERAS Erasca, Inc.

QT92

Latest market price

14.35

-0.63-4.21%

Overview Short InterestFilings

ERASQT92Erasca, Inc.·NASDAQ

Overview Short InterestFilings

14.35-4.21%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PTCT-6.97%$59.97 CRSP-5.23%$51.42 DFTX-4.29%$36.33 TVTX-0.36%$50.39 SRRK-0.63%$43.90 COGT-2.94%$31.02 DNTH-0.39%$82.38 MIRM-1.61%$85.00

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.95	Insider Own	12.08%	Shs Outstand	349.76M	Perf Week	-0.28%

Market Cap	5.02B	Forward P/E	—	EPS next Y	-0.62	Insider Trans	0.00%	Shs Float	247.18M	Perf Month	-1.58%

Enterprise Value	4.79B	PEG	—	EPS next Q	-0.13			Short Float	14.95%	Perf Quarter	-19.56%

Income	-287.00M	P/S	—	EPS this Y	—			Short Ratio	8.66	Perf Half Y	43.07%

Sales	0.00	P/B	13.86	EPS next Y	—	ROA	-66.02%	Short Interest	36.96M	Perf YTD	285.75%

Book/sh	1.03	P/C	18.66	EPS next 5Y	—	ROE	-80.43%	52W High	24.28 -40.90%	Perf Year	508.05%

Cash/sh	0.77	P/FCF	—	EPS past 3/5Y	—	ROIC	-37.52%	52W Low	2.11 580.09%	Perf 3Y	561.29%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	5.48% 6.67%	Perf 5Y	-24.03%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.97	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	8.29	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	45.29	Recom	2.18

Dividend Gr. 3/5Y	—	Current Ratio	8.29	EPS Q/Q	-16.67%	SMA20	-2.26%	Beta	0.71	Target Price	21.43

Payout	0.00%	Debt/Eq	0.11	Sales Q/Q	—	SMA50	-7.32%	Rel Volume	0.83	Prev Close	14.98

Employees	103	LT Debt/Eq	0.11	Earnings	Nov 11	SMA200	-4.35%	Avg Volume	4.42M	Price	14.35

IPO Date	Jul 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-25.71% —	Net Debt/EBITDA	—	Volume	3,691,140	Change	-4.21%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-13-26	Reiterated	Guggenheim	Buy	$12 → $21
Aug-12-26	Reiterated	HC Wainwright & Co.	Buy	$22
Jul-20-26	Reiterated	Morgan Stanley	Equal Weight	$10 → $21
Jul-14-26	Reiterated	Jefferies		$6.00 → $24
Jul-14-26	Reiterated	HSBC		$20
Jun-04-26	Reiterated	Wolfe Research		$16
Jun-04-26	Upgrade	B of A Securities	Underperform → Neutral
May-12-26	Reiterated	Mizuho	Outperform	$5.00 → $26
Apr-27-26	Reiterated	Stifel Nicolaus		$20 → $30
Mar-10-26	Reiterated	Stifel Nicolaus		$10 → $20

Latest News· Times ET

Oct-27-26

Oct-27-2606:39PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERASglobenewswire.com

02:15PM

Erasca (ERAS), What Is Driving Attention Around The Stock Today?Yahoo

Oct-23-26

Oct-23-2604:09PM

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Lawbusinesswire.com

Oct-22-26

Oct-22-2610:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASprnewswire.com

Oct-20-26

Oct-20-2604:02PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASglobenewswire.com

Oct-19-26

Oct-19-2602:08AM

Erasca (ERAS) Stock Looks Above Fair Value After Its 5x RunYahoo

Oct-18-26

Oct-18-2602:21AM

Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?defenseworld.net

Oct-15-26

Oct-15-2612:09PM

Erasca, Inc.: The Discount RevMed?SeekingAlpha

08:30AM

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalfglobenewswire.com

Oct-06-26

Oct-06-2612:31AM

Verastem: A Two-For-One Clinical Readout In October And A Commercial LaunchSeekingAlpha

Oct-05-26

Oct-05-2610:43AM

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Followerseekingalpha.com

Oct-03-26

Oct-03-2604:44AM

Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09defenseworld.net

Sep-22-26

Sep-22-2612:34PM

ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Dutyglobenewswire.com

08:30AM

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015globenewswire.com

Sep-21-26

Sep-21-2609:27AM

Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claimsglobenewswire.com

Company

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	—	—	—	—
Cost of Goods Sold Incl. D&A	2	3	0	4	—	—	—	—
Gross Profit	-2	-3	0	-4	—	—	—	—
Selling, General and Administrative Excl. Other	42	39	42	38	—	—	—	—
Research and Development	108	93	115	104	—	—	—	—
Other Operating Expense	2	-4	23	-4	—	—	—	—
Operating Income	-154	-131	-180	-142	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-134	7	18	16	—	—	—	—
Net Income Before Taxes	-287	-125	-162	-125	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—
Consolidated Net Income	-287	-125	-162	-125	—	—	—	—
Net Income From Continuing Operations	-287	-125	-162	-125	—	—	—	—
Net Income	-287	-125	-162	-125	—	—	—	—
EPS (Recurring)	-0.95	-0.44	-0.69	-0.83	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.95	-0.44	-0.69	-0.83	—	—	—	—
EPS (Diluted)	-0.95	-0.44	-0.69	-0.83	—	—	—	—
EBITDA	-284	-121	-153	-121	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	311	284	234	150	—	—	—	—
Market Capitalization	4,463	1,056	587	320	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garner Ebun	Chief Legal Officer	Apr 01 '26	Option Exercise	1.70	80,000	136,000	105,076	Apr 03
Garner Ebun	Chief Legal Officer	Apr 01 '26	Sale	16.40	80,000	1,312,000	25,076	Apr 03
Morris Shannon	Chief Medical Officer	Mar 04 '26	Option Exercise	1.70	20,000	34,000	20,000	Mar 06
Morris Shannon	Chief Medical Officer	Mar 04 '26	Sale	15.04	20,000	300,760	0	Mar 06
Morris Shannon	Chief Medical Officer	Mar 04 '25	Option Exercise	1.70	20,000	34,000	515,800	Mar 06
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Sale	5.59	120,000	670,812	25,076	Jan 08
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Option Exercise	1.70	120,000	204,000	145,076	Jan 08
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '25	Option Exercise	1.70	120,000	204,000	360,000	Jan 08
Casdin Alexander W.	Director	May 21 '24	Buy	2.27	80,000	181,920	573,974	May 22
Start Valerie Denise Harding	Director	Dec 06 '23	Buy	1.85	10,000	18,480	20,000	Dec 08
Lim Jonathan E	Chairman & CEO	Dec 06 '23	Buy	1.72	278,150	478,418	12,899,360	Dec 06
Lim Jonathan E	Chairman & CEO	Dec 05 '23	Buy	1.69	721,850	1,217,761	12,899,360	Dec 06
Casdin Alexander W.	Director	Dec 04 '23	Buy	1.66	30,000	49,785	493,974	Dec 04
Lim Jonathan E	Chairman & CEO	Oct 05 '23	Buy	2.03	1,000,000	2,026,000	19,456,216	Oct 10
Lim Jonathan E	Chairman & CEO	Jun 08 '23	Buy	2.75	100,000	275,000	18,396,216	Jun 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.